Malignancies in Systemic Lupus Erythematosus

Hiromi Tissera; Ann E. Clarke; Rosalind Ramsey Goldman; Caroline Gordon; James E. Hansen; Sasha Bernatsky

doi:10.1016/B978-0-12-801917-7.00046-2

Malignancies in Systemic Lupus Erythematosus

Hiromi Tissera^*, Ann E. Clarke, Rosalind Ramsey Goldman, Caroline Gordon, James E. Hansen, Sasha Bernatsky

^*Corresponding author for this work

Medicine, Rheumatology Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear, but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers. Hormonal changes, genetic factors, and drug exposures are discussed as potential reasons for the unique cancer profile in SLE, compared to the general population.

Original language	English (US)
Title of host publication	Systemic Lupus Erythematosus
Subtitle of host publication	Basic, Applied and Clinical Aspects
Publisher	Elsevier Inc
Pages	411-415
Number of pages	5
ISBN (Electronic)	9780128020098
ISBN (Print)	9780128019177
DOIs	https://doi.org/10.1016/B978-0-12-801917-7.00046-2
State	Published - 2016

Keywords

Breast cancer
Cancer incidence
Cervical cancer
Endometrial cancer
HPV
Immunosuppressive drugs
Lung cancer
Lymphoma
Malignancy
Ovarian cancer
Prostate cancer
Systemic lupus erythematosus

ASJC Scopus subject areas

General Medicine
General Immunology and Microbiology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-801917-7.00046-2

Cite this

@inbook{85209e6f08e0497b9d2c3e1ec489bc58,

title = "Malignancies in Systemic Lupus Erythematosus",

abstract = "This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear, but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers. Hormonal changes, genetic factors, and drug exposures are discussed as potential reasons for the unique cancer profile in SLE, compared to the general population.",

keywords = "Breast cancer, Cancer incidence, Cervical cancer, Endometrial cancer, HPV, Immunosuppressive drugs, Lung cancer, Lymphoma, Malignancy, Ovarian cancer, Prostate cancer, Systemic lupus erythematosus",

author = "Hiromi Tissera and Clarke, {Ann E.} and Goldman, {Rosalind Ramsey} and Caroline Gordon and Hansen, {James E.} and Sasha Bernatsky",

year = "2016",

doi = "10.1016/B978-0-12-801917-7.00046-2",

language = "English (US)",

isbn = "9780128019177",

pages = "411--415",

booktitle = "Systemic Lupus Erythematosus",

publisher = "Elsevier Inc",

}

TY - CHAP

T1 - Malignancies in Systemic Lupus Erythematosus

AU - Tissera, Hiromi

AU - Clarke, Ann E.

AU - Goldman, Rosalind Ramsey

AU - Gordon, Caroline

AU - Hansen, James E.

AU - Bernatsky, Sasha

PY - 2016

Y1 - 2016

N2 - This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear, but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers. Hormonal changes, genetic factors, and drug exposures are discussed as potential reasons for the unique cancer profile in SLE, compared to the general population.

AB - This chapter focuses on cancer in systemic lupus erythematosus (SLE). While the overall cancer incidence rate in SLE patients compared to the general population is only slightly increased, there is a particularly high risk of lymphoma in SLE. The specific underlying pathophysiology is unclear, but appears to be multifactorial. On the other hand, certain hormone-sensitive cancers appear to be less common in SLE patients than in the general population. In particular, SLE patients have a reduced risk of breast, ovarian, endometrial, and prostate cancers. Hormonal changes, genetic factors, and drug exposures are discussed as potential reasons for the unique cancer profile in SLE, compared to the general population.

KW - Breast cancer

KW - Cancer incidence

KW - Cervical cancer

KW - Endometrial cancer

KW - HPV

KW - Immunosuppressive drugs

KW - Lung cancer

KW - Lymphoma

KW - Malignancy

KW - Ovarian cancer

KW - Prostate cancer

KW - Systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=84967163402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967163402&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801917-7.00046-2

DO - 10.1016/B978-0-12-801917-7.00046-2

M3 - Chapter

AN - SCOPUS:84967163402

SN - 9780128019177

SP - 411

EP - 415

BT - Systemic Lupus Erythematosus

PB - Elsevier Inc

ER -

Malignancies in Systemic Lupus Erythematosus

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this